Biotechnology

ETANA HAS SECURED B ROUND FINANCING

JAKARTA, Indonesia, Sept. 28, 2022 /PRNewswire/ -- PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has secured B round of financing led by Yunfeng Capital and followed by HighLight Capital. This round of financing will be mainly used for further strengthening ...

2022-09-28 09:00 4058

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

MELBOURNE, Australia, Sept. 28, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a pivotal Phase III registration study that will bridge ...

2022-09-28 06:50 1334

Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announces that it has completed the first subject dosing in a phase I study of HBM9378 (or SKB378 as referred to by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd...

2022-09-27 21:40 1254

CP KELCO PARTNERS WITH EXOPOLYMER TO BRING NEXT-GENERATION FUNCTIONAL BIOPOLYMERS TO MARKET

ATLANTA, Sept. 27, 2022 /PRNewswire/ -- CP Kelco, a global leader of nature-based ingredient solutions that is owned by J.M. Huber Corporation, and ExoPolymer, Inc., a biotechnology startup company focused on developing new-to-the-world, polysaccharide-based biopolymers, are excited to announce a ...

2022-09-27 21:00 1284

Metabolon Expands Data Access Strategy to Include Health for Life in Singapore (HELIOS) Study

Metabolon to collaborate with NTU Singapore's medical school to identify biomarkers for the prevention, diagnosis, and treatment of disease. MORRISVILLE, N.C., Sept. 27, 2022 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions that advance a wide variety of res...

2022-09-27 19:57 1475

Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics

The partnership combines Sciwind's expertise in disease biology and clinical development capabilities with SynerK's proprietary conjugate-based siRNA delivery technology and expertise in developing RNAi therapeutics SAN FRANCISCO, Calif. and HANGZHOU, China, Sept. 27, 2022 /PRNewswire/ -- Sciwin...

2022-09-27 08:00 1862

First Patient Enrolled in ProstACT TARGET Study

MELBOURNE, Australia, Sept. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and GenesisCare, the largest provider of integrated cancer care inAustralia, today announce that a first patient has been enrolled in the Phase II ProstACT TARGET study of Telix's pro...

2022-09-27 05:00 1639

Bioheng Biotech Announces Publication of Impressive Results with CD7-targeted allogeneic CAR-T cell therapy for Relapsed or Refractory T Cell Malignancies

NANJING and HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd, a clinical-stage biotechnology company focused on developing novel cellular immunotherapy, today announced that a phase I clinical study results of RD13-01, an anti-CD7 universal CAR-T therapy product, h...

2022-09-26 21:00 1515

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

* Data demonstrated that a single administration of BRII-296 at 600 mg delivered a favorable pharmacokinetic profile and is safe and well-tolerated in healthy subjects * Findings suggest BRII-296 has potential to provide a safe and effective, one-time injectable treatment option to people wit...

2022-09-26 20:00 2042

PharmAbcine to Participate in BIO-Europe 2022

DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place ...

2022-09-26 20:00 1177

WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

New facility expands integrated drug product R&D and manufacturing services to global customers SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- WuXi STA, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of its first high potency (HP) o...

2022-09-26 20:00 1379

CellResearch Corporation (CRC) to present promising new stem cell products for the treatment of chronic diabetic foot ulcers at the world's premier diabetic foot conference (DFCon) in Los Angeles

-  CRC data on cord lining media for the treatment of diabetic foot ulcers has been accepted at the DFCon, with DrWong Keng Lin Francis, CRC's latest KOL, presenting his findings to world leaders in the field of DFU. -  Similarly, the results of Corlicyte™'s Phase 1 study on the treatment of chro...

2022-09-26 13:44 1399

CellOrigin Biotech Announces Global Strategic Collaboration with Qilu Pharma to Develop "Off-the-Shelf" CAR-iMAC Cell Therapy

HANGZHOU, China, Sept. 26, 2022 /PRNewswire/ -- CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric An...

2022-09-26 12:31 1300

Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases

Advancement highlights Everest's potential in providing first-in-class therapies to global patients with glomerular disease SHANGHAI, Sept. 26, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focu...

2022-09-26 08:00 2235

Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities

SINGAPORE, Sept. 23, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Sc...

2022-09-23 17:00 1678

WINNERS OF THE 2023 BREAKTHROUGH PRIZES IN LIFE SCIENCES, MATHEMATICS AND FUNDAMENTAL PHYSICS ANNOUNCED

$15.75 Million in Prizes Awarded for Predicting Protein Structure with Deep Learning, Pioneering Field of Quantum Information, and Discoveries with Applications from Treating Neurodegenerative Disease to Optimizing Video Transmission Breakthrough Prize in Life Sciences Awarded to Clifford P. Bra...

2022-09-22 21:25 1892

Cellenkos Receives FDA Clearance of Investigational New Drug (IND) Application for CK0803 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

-- CK0803 are neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg) cells -- CK0803 represents the company's fifth program to receive IND Clearance utilizing Cellenkos' proprietaryCRANE™ technology HOUSTON, Sept. 22, 2022 /PRNewswire/ -- Cellenkos, Inc., a clinical stage bio...

2022-09-22 13:59 1212

Ascentage Pharma Announces Phase I/II Data of Olverembatinib (HQP1351) Published in the Journal of Hematology & Oncology, Further Validating the Drug's Best-in-Class Potential

SUZHOU, China and ROCKVILLE, Md., Sept. 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the results from a Phase I and Phase II study of ...

2022-09-21 22:49 1387

Far Eastern New Century won the "Sustainability & Innovation Award" from ITMF Awards 2022 with FENC® TOPGREEN® Bio3

FENC® TOPGREEN® Bio3, World No.1 Fabric made from waste gas reuse technology & N66 solution dye. TAIPEI, Sept. 21, 2022 /PRNewswire/ -- As the pioneer in innovation and sustainability, Far Eastern New Century Corporation (FENC) is able to provide solutions to lower the environmental impact for b...

2022-09-21 20:00 1647

HIKE Capital rides green wave to seize future

BEIJING and SINGAPORE, Sept. 21, 2022 /PRNewswire/ -- As the world is undergoing an energy restructuring, HIKE Capital, a leading founders' fund in China, has been committed to seizing the opportunities that emerged in the new era, which has been shaped by carbon reduction and digital technology. ...

2022-09-21 13:53 1669
1 ... 108109110111112113114 ... 278